Pentixapharm Holding AG (VIE:PTPN)

Market Cap	49.57M -39.3%
Revenue (ttm)	636.00K -96.2%
Net Income	-16.51M
EPS	-0.67
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	26
Open	1.880
Previous Close	1.904
Day's Range	1.880 - 2.020
52-Week Range	1.330 - 3.550
Beta	n/a
RSI	57.31
Earnings Date	Mar 26, 2026

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2019
• Employees: 64
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: PTPN

Financial Performance

In 2025, Pentixapharm Holding AG's revenue was 636,000, a decrease of -54.65% compared to the previous year's 1.40 million. Losses were -16.51 million, 18.1% more than in 2024.